Background: Cardiotrophin-1 (CT-1) is an important inflammatory cytokine, its
Introduction
Heart failure remains a leading cause of morbidity and mortality. The outcome of patients post myocardial infarction has improved somewhat due to advances in medical therapy, however the associated morbidity and mortality remains the same.
Clinical features may be useful for predicting patients who are at risk of developing such complications post AMI but lack sensitivity and specificity. Biomarkers are emerging as a useful tool in predicting prognosis in patients after an AMI. B type natriuretic peptide and its more stable counterpart N terminal pro B type natriuretic peptide (NT-proBNP) have shown some promise in this area and are able to predict death or heart failure. 1 Newer peptides are emerging which may be of some use, particularly in a multi-marker strategy with NT-proBNP.
Cardiotrophin-1 (CT-1) is a 201 amino-acid inflammatory cytokine, which belongs to the interleukin-6 family. 2 CT-1 induces cardiac myocyte hypertrophy, 3 adding sarcomeres in series rather than in parallel and leading to increased cardiac myocyte size due to an increase in cell length, with little change in width. 4 It binds to the glycoprotein 130 (gp130) and leukaemia inhibitory factor receptor. 5 The actions of CT-1 are dependent on receptor binding but it has been shown to have protective effects on adult rat or human cardiomyocytes when added prior to ischaemia and at reperfusion. 6, 7 When given to rats it causes a decline in blood pressure and a reflex increase in heart rate. 8 CT-1 has been shown to be raised in patients following an AMI and unstable angina 9, 10 and in those patients with echocardiographic heart failure compared to controls. 11 Most recently CT-1 has been shown to be raised in hypertension. 12, 13 It is unclear however whether CT-1 has a protective or detrimental effect in AMI as it triggers hypertrophy and anti-apoptotic pathways by distinct mechanisms. The role of CT-1 in the prognostication of AMI is unknown. In this 3 study we investigated whether CT-1 would be of benefit in determining the prognosis of AMI particularly death and heart failure which remain a leading cause of mortality and morbidity. We compared this with N terminal pro B type natriuretic peptide (NTproBNP), which has been shown to be of prognostic benefit in this group of patients.
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Methods
Study population
We studied 291 consecutive acute myocardial infarction patients admitted to the 
Plasma samples
Blood measurement was made at 25-48hrs after the onset of chest pain for determination of plasma CT-1 and NT-proBNP. After 15 minutes bed rest, 20mL
blood was collected into tubes containing EDTA and aprotinin. All plasma was stored at -70°C until assayed in a single batch.
Echocardiography
Transthoracic echocardiography was performed in patients using a Sonos 5500 and 4=dyskinesis (Paradoxical Motion), and dividing the total by the number of segments scored. Left ventricular ejection fraction (LVEF) was calculated using the biplane method of discs formula. 16 Inter and intra coefficients of variation were 9.3% and 11.4% respectively.
NT-proBNP assay
Our NT-proBNP assay was based on a non-competitive assay. Sheep antibodies were raised to the N-terminal of human NT-proBNP and monoclonal mouse antibodies were raised to the C-terminal. The N-terminal IgG was affinity-purified and biotinylated. Samples or NT-proBNP standards were incubated in C-terminal IgGcoated wells with the biotinylated N-terminal antibody for 24 hours at 4°C. Detection was with methyl-acridinium ester (MAE)-labelled streptavidin. 17 The lower limit of detection was 0.3 fmol/ml. Inter and intra coefficients of variation were 2.3% and 4.8% respectively. There was no cross reactivity with atrial natriuretic peptide, BNP, or C-type natriuretic peptide.
CT-1 assay
The CT-1 assay was based on a non-competitive assay. ELISA plates were coated with anti-rabbit IgG (100ng/well). The capture antibody was a rabbit anti-CT-1
antibody (100ng/100μL assay buffer, Peprotech Inc, Rocky Hill, NJ), and detection employed a biotinylated mouse monoclonal antibody (50ng/100μL assay buffer, BioVendor Laboratory Medicine, Modrice, Czech Republic). Plasma samples (50 μL)
or CT-1 standards were incubated for 24 hours at 4°C. Following washes; detection was performed using methyl-acridinium ester (MAE)-labelled streptavidin. Intra-and inter-assay coefficients of variation were found to be less than 10%.
End points
We assessed the value of both CT-1 and NT-proBNP for the prediction of death or heart failure. A combined primary endpoint consisting of death and rehospitalization for heart failure was used. Hospitalization for heart failure was defined as a hospital admission for which heart failure was the primary reason and was verified by contacting each patient and review of their notes. Death endpoints were obtained by reviewing the Office of National Statistics Registry which records all hospital deaths.
There was a minimum 30-day follow-up of all patients.
Statistical analysis
Statistical analyses were performed on SPSS Version 12 (SPSS Inc, Chicago, Illinois). The continuous variables in the two independent groups were compared 6 using the Mann Whitney U test and results for continuous variables are displayed as median (range). Endpoints were analysed as categorical for CT-1 and NT-proBNP.
Spearman's correlations were performed and binary logistic regression analyses were conducted which included baseline patient characteristics (age, sex, serum creatinine, Killip class, territory of AMI and whether the patient received thrombolysis or not) and peptide markers (including troponin I), to test the independent predictive power of the peptides above and below the median for death or heart failure as defined above. NT-proBNP and CT-1 were normalised by log transformation. Thus, odds ratios and hazard ratios refer to a tenfold rise in the levels of these markers. To identify the independent predictors of death or heart failure, Cox proportional hazard analyses was used. Kaplan Meier survival curves were generated to visualise the relationship between the peptides NT-proBNP and CT-1 and the primary endpoint as time to first event. To compare the predictive value of NT-proBNP and CT-1, receiver-operating characteristic (ROC) curves were generated at 438 days and the area under the curves (AUC) was calculated. A p value of less than 0.05 was deemed to be statistically significant. Power calculations showed that for a 2.5 fold difference in CT-1 values between those with the primary endpoint and the event free group, the number of patients needed was 266 to detect a difference with a power of 90% at p<0.05.
Results
Patient characteristics
The demographic features of the patient population are shown in Table 1 
CT-1 levels in patients and controls
Plasma levels of CT-1 in patients with AMI ranged from 0.03-453.3fmol/ml with a median of 0.77fmol/ml. CT-1 was higher in patients following AMI compared to was measured daily in a subset of 50 patients revealing a significant overall difference in secretion over the 5 days (p<0.0001). There was also a significant difference in secretion when day 1 was compared to days 2, 3 and 4 (p<0.0001) and is shown in figure 1 .
There was no correlation of CT-1 with age (r= 0.07, p= 0.228), LVWMI (r= -0.042, p= 0.507) or heart failure (r= 0.064, p> 0.346). CT-1 did not differ significantly according to gender, smoking status, the presence or absence of diabetes mellitus, hypertension, previous MI diagnosis, hypercholesterolemia or whether a patient received thrombolyis or not. There was no correlation however between NT-proBNP and CT-1 (r=0.087, p=0.138).
NT-proBNP levels in patients and controls
NT-proBNP was significantly elevated in AMI compared with controls (Median figure 2 .
Relationship between CT-1 and echocardiographic parameters
For the whole population, mean LVWMI was 1.52 (range 1.08-2.75) and EF was 38%
(range 12-49%). The LVWMI score in those subjects with anterior AMI was higher 
CT-1 and NT-proBNP as predictors of death or heart failure
CT-1 was raised in patients with death or heart failure compared to survivors (median 
Discussion
Reperfusion therapy has improved mortality post MI, however the outcome of patients despite this is still poor; 18 for this reason risk stratification remains important and may be useful in helping to select treatment regimes in the future. A multimarker strategy has benefits in that it utilizes the different pathways that are involved in the development and outcome of an AMI in the hope that complementary information can be gained. 19 The aim of this study was to assess the utility of CT-1 and NT-proBNP in determining the prognosis of AMI patients. The results of this study confirm the independent prognostic values of early CT-1 and NT-proBNP levels in determining death or heart failure in patients who have an AMI. The information has been gained with a single blood test taken between 25-48 hours. Unlike NT-proBNP there was no correlation of CT-1 with age or sex, which may make it a more discerning marker.
The predictive value of CT-1 provides risk prediction independent of NT-proBNP and other known clinical predictors of death or heart failure. Both CT-1 and NT-proBNP are raised after an AMI and their secretion patterns differ over the 5 days following an AMI with significant differences noted for both peptides. CT-1 is raised early after an AMI with levels falling rapidly after the first 24 hours then rising again. This suggests that there may be a stored pool of CT-1, which is released after an AMI, with the second wave of release due to new synthesis of the peptide. The likely source of CT-1 is unknown however a possible source is the left ventricle. We have shown a weak but positive correlation between CT-1 and LVWMI. Other possible sources could well be the atria; CT-1 has been shown to be raised in the atrial tissue of WKY rats. 13 We used CT-1, an inflammatory cytokine and NT-proBNP, which is a more stable byproduct in the production of BNP. 20 We have clearly shown the benefit of using each peptide alone at predicting death or heart failure; indeed NT-proBNP is a wellestablished marker for predicting LV dysfunction and prognosis after an acute myocardial infarction. 1 Using a combination of CT-1 and NT-proBNP in a multimarker risk stratification approach in patients gives an increased area under the ROC curve and more predictive accuracy.
The relationships for prediction exists in quite a heterogeneous group of patients (NSTEMI, STEMI, previous history of cardiovascular diseases and age etc) it would be interesting to see if a separation could be made on the basis of presenting diagnosis. What also remains to be seen is the utility of CT-1 at being able to individually predict death or heart failure however a larger powered study would be necessary to answer such a question.
11
In conclusion, this is the first report of CT-1 as a prognostic marker of death or heart failure in patients with AMI. This study confirms previous findings that CT-1 is involved during an AMI and it may be useful in a multimarker approach with NTproBNP for risk stratification in AMI patients. 
Legends
